As one of seven generic drug manufacturers selected by MPP and becoming a sub-licensee of Shionogi – a Japanese pharmaceutical manufacturer to produce of XOCOVA™ drug, generic version. Stellapharm is honored and proud to have contributed to repelling the COVID-19 pandemic with drugs. This is the third oral product in the world to be recognized
On February 21, 2022, Stellapharm officially signed a contract with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce a generic version of Pfizer’s oral COVID-19 treatment, nirmatrelvir, which will be co-packaged with ritonavir, under the voluntary licensing agreement between Pfizer and the MPP.
HÀ NỘI — The Drug Administration of Việt Nam under the Ministry of Health has issued the list of three COVID-19 treatment drugs produced in Việt Nam that contain the antiviral ingredient Molnupiravir, which have been granted certificates of registration for conditional use. The three products – Molravir 400mg produced by Boston Việt Nam Pharma (based in
20 January 2022 Geneva – The Medicines Patent Pool (MPP) announced today that it has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs). The sublicence agreements are the result of the voluntary licensing agreement signed by MPP and
On January 10, 2022, Stellapharm officially signed an agreement with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce the COVID-19 treatment molnupiravir under the "Voluntary Licensing" program for MSD, a trade name of Merck & Co., Inc., Kenilworth, NJ, USA.
in December 23, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom
Nov 10 (Reuters) – Merck & Co Inc (MRK.N) and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir. Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness
Washington (AFP) – US pharmaceutical giant Merck has vowed to avoid the pitfalls of the global Covid vaccine rollout by ensuring its new anti-coronavirus pill is made available in wealthy and poor countries at almost the same time. Paul Schaper, the company’s executive director of global public policy, told AFP that Merck began working on
Molnupiravir can be taken as a pill instead of injection or intravenous administration. Antiviral drug Molnupiravir, used for treating mild to moderate Covid-19 infections, is set to enter the Indian markets within days, an official confirmed on Wednesday. Manufactured by US drug companies Merck, Sharp and Dohme, Molnupiravir is among the first proven drugs to
The antiviral was found to be safe and effective following a stringent review of the available evidence. The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory
The Ministry of Health has authorized the use of COVID-19 drug Molnupiravir for emergency conditions. The Ministry said that Molnupiravir is an oral and oral anti-COVID pill that is safe and highly effective for treating COVID-19. Molnupiravir is manufactured by Mylan Laboratories Limited, based in India. The Ministry of Health states that the conditions for
Sept 29 (Reuters) – Laboratory studies show that Merck & Co’s (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Since molnupiravir does not target the spike protein of the virus – the target of
(CNN)_During the global scramble to secure vaccines, many countries in Asia-Pacific were slow off the mark. This time, they’re not making the same mistake.Countries around the region are rushing to place orders for the latest weapon against Covid-19: an antiviral pill that isn’t even authorized for use yet. Molnupiravir — produced by US pharmaceutical company
(Reuters) – The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday. The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.
In a late-stage clinical trial, a new antiviral pill halved the chance that patients diagnosed with COVID-19 would end up in the hospital or die from the disease, the drugmaker Merck announced Friday (Oct. 1). The drug, called molnupiravir, was developed by Merck and Ridgeback Biotherapeutics and could be the first oral medication specifically approved
By Stephanie NolenOct. 17, 2021 Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs. Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear
Merck and Ridgeback Biotherapeutics said Friday they’ve developed a drug that reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid. The companies plan to seek emergency authorization for the antiviral Covid treatment after the medicine showed “compelling results” in clinical trials. The drug, molnupiravir, is
A novel coronavirus, originally identified in Wuhan City, China, was reported to the World Health Organization on 31 December 2019, and the associated disease has subsequently become a worldwide pandemic. An effective antiviral therapeutic has since been intensively sought. Coronaviruses use an RNA-dependent RNA polymerase (RdRp) for the replication and transcription of their RNA genome.
[Updated to July 2021] The results of the trial demonstrate the safety, tolerability, and antiviral efficacy of molnupiravir to reduce replication of SARS-CoV-2 and accelerate clearance of infectious virus and support ongoing trials of molnupiravir to prevent progression of COVID-19 and eliminate onward transmission of SARS-CoV-2. After more than one year into the coronavirus disease
According to Minister of Health Nguyen Thanh Long, the Ministry of Health and the Department of Health of Ho Chi Minh City start using the experimental antiviral drug Molnupiravir to treat Covid-19 patients with mild-symptom from August 27, 2021. He said this while inspecting the Covid-19 prevention and control task in Ho Chi Minh City’s
Since the beginning of February this year, many consignments of Stella's pharmaceutical products with a total of nearly 200 million units have been urgently exported by air to markets in Germany, France, Austria, Belgium, Ireland, etc.
STADA - VN JOINT VENTURE CO., LTD. officially changed its name to STELLAPHARM J.V. CO., LTD. since 16 August 2019.